Please login to the form below

Not currently logged in

bluebird bio’s beta thalassaemia gene therapy Zynteglo scores promising long-term data

Results presented at annual American Society of Haematology (ASH) meeting

bluebird bio has revealed some long-term data for its gene therapy betibeglogene autotemcel, which is marketed as Zynteglo in the European Union.

bluebird bio announced the new long-term data at the annual American Society of Haematology (ASH) meeting, reflecting up to six years of safety and efficacy data for the gene therapy in patients with transfusion-dependent beta thalassaemia (TDT).

Zynteglo, or beti-cel, is a one-time gene therapy designed to add functional copies of a modified form of the β-globin gene to a patient’s blood stem cells.

This gives patients the potential to produce haemoglobin (Hb) A, which is a gene therapy derived adult Hb.

This is particularly important as TDT patients have mutations in the β-globin gene that cause reduced or significantly reduced Hb levels. This means that people living with TDT need chronic blood transfusions to maintain adequate Hb levels in order to survive.

Among 32 patients enrolled in the 13-year, long-term LTF-303 study, 64% of patients treated in the phase 1/2 portion and 90% in the phase 2 portion achieved transfusion independence (TI).

In bluebird bio's studies of Zynteglo, TI is defined as no longer needing red blood cell transfusions for at least 12 months, while maintain a weighted average Hb of at least 9 g/dL.

In the LTF-303 study, all patients who achieved TI remained free from transfusions , with the median duration of ongoing TI coming in at 39.4 months.

bluebird bio also revealed data from 24 paediatric patients who were treated with the gene therapy in the phase 3 Northstar-2 and Northstar-2 studies, reflecting a median follow-up of 15.5 months.

Across these studies, following treatment with Zynteglo, 87% of evaluable patients under the age of 16 years achieved TI. bluebird bio added that as of 3 March 2020 these patients continued to be free of transfusion for a median duration of 14.9 months.

“All of the patients in our phase 3 studies who achieved transfusion independence have maintained it, with the durability of the treatment effect underscored by patients from our earlier studies reaching their five-year anniversaries of freedom from transfusions,” said David Davidson, chief medical officer, bluebird bio.

“Moreover, transfusion independence has been observed in paediatric, adolescent and adult patients and across genotypes – suggesting outcomes with this gene therapy may be consistent regardless of age or genotype,” he added.

Article by
Lucy Parsons

9th December 2020

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company
Page & Page and Partners

For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....